BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

...million in a series A round. Investors included Samsung Venture Investment Corp., Shinhan Venture Investment, Smilegate Investment...
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...LifeForce Capital, LifeSci Venture Partners, Menlo Ventures, Nest.Bio, Noveus Capital, Pear VC, Ridgeback Capital and Smilegate Investment.Herberts...
BioCentury | Aug 14, 2019
Financial News

D&D raises $137M to fund inflammation tech out of JHU

South Korea’s D&D Pharmatech raised $137.1 million in a series B round to push forward the pipelines of its trio of inflammation-focused subsidiaries. Founded in 2014, D&D Pharmatech Co. Ltd. (Gyeonggi-do, South Korea) is the...
BioCentury | Jul 17, 2019
Financial News

Korea’s Orum stays local with $30M round to build out cell-penetrating platform

...Korea, Orum raised $30 million in a series B round from new investors IMM Investment, Smilegate Investment...
Items per page:
1 - 4 of 4
BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

...million in a series A round. Investors included Samsung Venture Investment Corp., Shinhan Venture Investment, Smilegate Investment...
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...LifeForce Capital, LifeSci Venture Partners, Menlo Ventures, Nest.Bio, Noveus Capital, Pear VC, Ridgeback Capital and Smilegate Investment.Herberts...
BioCentury | Aug 14, 2019
Financial News

D&D raises $137M to fund inflammation tech out of JHU

South Korea’s D&D Pharmatech raised $137.1 million in a series B round to push forward the pipelines of its trio of inflammation-focused subsidiaries. Founded in 2014, D&D Pharmatech Co. Ltd. (Gyeonggi-do, South Korea) is the...
BioCentury | Jul 17, 2019
Financial News

Korea’s Orum stays local with $30M round to build out cell-penetrating platform

...Korea, Orum raised $30 million in a series B round from new investors IMM Investment, Smilegate Investment...
Items per page:
1 - 4 of 4